Maik W. Jornitz elected Chair of the Board of the global Parenteral Drug Association
Advertisement
Maik W. Jornitz, Group Vice President of Global Marketing & Product Management for Filtration | fermentation Technologies at Sartorius Stedim Biotech, is now Chair of the Board of the Parenteral Drug Association (PDA). The PDA, headquartered in Bethesda, Maryland, USA, is a global not-for-profit organization providing science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community.
Maik W. Jornitz, Group Vice President of Global Marketing & Product Management for Filtration | Fermentation Technologies at Sartorius Stedim Biotech.
Sartorius Stedim Biotech
Maik Jornitz has been an active member of the PDA since 1994, holding a number of voluntary functions. For instance, he was a member of the task forces that drafted technical reports on sterile filtration and depth filtration and headed the 2008 PDA Annual Meeting. He was elected in 2004 to the Board of Directors and has been Chair-Elect of the Board since 2007. In addition to Jornitz, the PDA Board consisting of 17 members includes representatives from the pharmaceutical companies Pfizer, Novartis, GlaxoSmithKline, Amgen, Baxter, Roche/Genentech, Abbott and Hoffmann-La-Roche. Maik Jornitz’s term as PDA Chair will run until the end of 2011.
Maik W. Jornitz has been with the Sartorius Group for 23 years. The biotech manager is an internationally recognized expert in filtration technologies with a focus on sterile filtration, process validation and integrity testing for biopharmaceutical applications. He has already authored and co-authored nine scientific books and seven chapters, and regularly publishes technical papers in scientific and trade journals.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Stora Enso enters into strategic partnership with Swedish University of Agricultural Sciences
Images of NMDA receptors help explain how they are affected by zinc and a drug
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies - Ikarovec is developing novel gene therapies to treat serious, but common eye diseases
The Linde Group and Algenol Biofuels agree to cooperate in CO2 and O2 management for biofuel production from algae
RNA Healer receives around one million euros for the development of a liver fibrosis therapy - MHH project wins start-up funding competition organised by Lower Saxony research incubator Institute for Biomedical Translation Lower Saxony.
Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders - Launch of Start-up QLi5 Therapeutics
Biomass for biofuels, biochemicals will more than triple to 3.7 billion tons in 2030
Thianthrenium chemistry allows for reactivity switch of a nucleophilic amino acid into a versatile intermediate - Useful and broadly applicable tool in the field of chemical biology
U.S. Department Of Defense selects Applied Biosystems for development of instrument system to identify infectious diseases
NLS Pharma acquires a portfolio of strategic patents - Critical step in the novel development of a potential non-amphetaminic stimulant for ADHD
